Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Scusami who wrote (11321)	11/17/1997 6:19:00 PM
From: John McCarthy	Respond to of 32384

Scusami - Sorry to put you thru the trouble. I have the article from IBD because I xerox and keep their bio-tech articles. There is nothing in the article to indicate the approximate time it was published. The last paragraph states that ... in the 1st qtr. they earned 4 cents .... and the price was 10.50. So it would have have to been after the 1st qtr. but I am not sure which year 97 or 96. In any event, she can get info about Diacrin from Yahoo, etc. and follow-up from there. DCRN is located in Charlestown, Mass. Much of the clinical research is being done at LEHEY HITCHCOCK CLINIC IN BOSTON. The president of the company is THOMAS FRASER. The product is called NeuroCell-PD. Genzyme Tissue Repair is funding much of the dev. cost ($40 mil.) They are talking in terms of a 1 time treatment costing $50,000. From the point this article was written there is another 2 years of development time required. Regards, John McCarthy